ZIMMER BIOMET HOLDINGS, INC. 
By WARSAW, Ind., April 24, 2014 /PRNewswire/ -- Zimmer Holdings, Inc. (NYSE and SIX: ZMH) today reported financial results for the quarter ended March 31, 2014. The Company reported first quarter net sales of $1.161 billion, an increase of 2.0% reported and an increase of 3.2% constant currency over the first quarter of 2013. Diluted earnings per share for the quarter were $1.29 reported and $1.50 adjusted, an increase of 6.4% adjusted over the prior year period.
http://photos.prnewswire.com/prnvar/20131216/MM33947LOGO
"Zimmer produced solid results during the first quarter, providing further validation of our long-term growth and stockholder value creation strategies," said David Dvorak, Zimmer President and CEO. "As we continue focus on the execution of our quality and operational excellence initiatives, we believe that the Company is well positioned for continued growth in the evolving global healthcare landscape through the ongoing development and commercialization of innovative and clinically relevant solutions. Looking ahead, we remain committed to enhancing value for our stockholders and strengthening our position as a global leader in musculoskeletal healthcare."
Net earnings for the first quarter were $221.5 million on a reported basis and $258.1 million on an adjusted basis, an increase of 7.2% adjusted over the prior year period. Operating cash flow for the first quarter was $188.8 million.
During the quarter, the Company utilized $400.5 million of cash to acquire 4.2 million shares. At the end of the first quarter, $599.5 million of share repurchase authorization remained available under the current program.
Also in the quarter, the Company paid $34.0 million in dividends and declared a first quarter dividend of $0.22 per share, an increase of 10% over the dividend declared for the prior year period.
Zimmer to Combine with Biomet
Zimmer also announced today that it has entered into a definitive agreement to acquire Biomet in a cash and stock transaction valued at approximately $13.35 billion, including the assumption of net debt. Please refer to the separate joint press release issued by Zimmer and Biomet today for additional details regarding the transaction.
Guidance
The Company reaffirmed its full-year revenue and updated earnings guidance for 2014. Full-year revenues are still expected to increase approximately 3.0% to 5.0% on a constant currency basis from 2013. The Company continues to estimate that foreign currency translation will decrease revenues by approximately 0.5% for the full year, resulting in reported revenue growth between 2.5% and 4.5%.
The Company's earnings guidance has been updated to give effect to a change in the anticipated number of diluted weighted average shares outstanding for 2014. The number is expected to be higher as a result of the discontinuation of previously guided share repurchases ahead of the announced transaction with Biomet. The Company now expects full-year 2014 diluted earnings per share to be in a range of $4.90 to $5.10 on a reported basis and $6.00 to $6.20 on an adjusted basis with the higher average shares. Prior guidance for full-year 2014 adjusted diluted earnings per share was $6.10 to $6.30. Consistent with the prior guidance, adjusted diluted earnings per share exclude estimated charges for inventory and manufacturing related expenses, quality and operational excellence initiatives, and special items of $250.0 million on a pre-tax basis, or approximately $1.10 per diluted share, on an after-tax basis. Additional costs connected to the pending transaction with Biomet which are not estimable at this time, shall also be excluded from the adjusted earnings measure.
Conference Call, Webcast and Presentation
The Company will conduct its first quarter 2014 investor conference call today, April 24, 2014, at 8:00 a.m. Eastern Time. The live audio webcast and accompanying presentation can be accessed via Zimmer's Investor Relations website at http://investor.zimmer.com. It will be archived for replay following the conference.
Individuals who wish to dial into the conference call may do so at (888) 878-3901. International callers should dial (706) 634-9520 and enter the conference ID15793245. A digital recording will be available. To access the recording, US/Canada callers should dial (855) 859-2056 or (800) 585-8367, or for International callers, dial (404) 537-3406, and enter the conference ID15793245.
Sales Table
The following table provides sales results by geographic segment and product category, as well as the percentage change compared to the prior year period on both a reported and constant currency basis.
NET SALES - THREE MONTHS ENDED MARCH 31, 2014
(in millions, unaudited)
Constant
Net Reported Currency
Sales % Change % Change
----- -------- --------
Geographic
Segments
Americas $638 1% 1%
Europe 327 6 4
Asia Pacific 196 - 8
---
Total 1,161 2 3
Product
Categories
Reconstructive
Americas 473 2 2
Europe 257 6 4
Asia Pacific 142 - 9
---
Total 872 3 4
Knees
Americas 284 3 3
Europe 131 7 5
Asia
Pacific 73 - 10
---
Total 488 4 5
Hips
Americas 150 (1) -
Europe 116 3 1
Asia
Pacific 66 (2) 7
---
Total 332 - 2
Extremities 52 9 9
Dental 61 2 2
Trauma 79 (3) (1)
Spine 48 1 1
Surgical and
other 101 1 3
About the Company
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer designs, develops, manufactures and markets orthopaedic reconstructive, spinal and trauma devices, dental implants, and related surgical products. Zimmer has operations in more than 25 countries around the world and sells products in more than 100 countries. Zimmer's 2013 sales were approximately $4.6 billion. The Company is supported by the efforts of more than 9,000 employees worldwide.
Website Information
We routinely post important information for investors on our website, www.zimmer.com, in the "Investor Relations" section. We use this website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors should monitor the Investor Relations section of our website, in addition to following our press releases, SEC filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, our website is not incorporated by reference into, and is not a part of, this document.
Note on Non-GAAP Financial Measures
As used in this press release, the term "adjusted" refers to operating performance measures that exclude inventory step-up and other inventory and manufacturing related charges, special items and certain tax adjustments. Included in special items are acquisition and integration costs and asset impairment charges related to prior acquisitions as well as employee termination benefits, consulting and professional fees, certain litigation matters, dedicated personnel expenses, certain contract terminations and asset impairment charges connected with global restructuring and operational excellence initiatives. The term "constant currency" refers to any financial measure that excludes the effect of changes in foreign currency exchange rates. Reconciliations of these non-GAAP measures to the most directly comparable GAAP measure are included in this press release.
Zimmer Safe Harbor Statement
This press release contains forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 based on current expectations, estimates, forecasts and projections about the orthopaedics industry, management's beliefs and assumptions made by management. Forward-looking statements may be identified by the use of forward-looking terms such as "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "assumes," "guides," "targets," "forecasts," "is confident that," and "seeks" or the negative of such terms or other variations on such terms or comparable terminology. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that could cause actual outcomes and results to differ materially. These risks and uncertainties include, but are not limited to: the success of our quality and operational excellence initiatives; price and product competition; changes in customer demand for our products and services caused by demographic changes or other factors; the impact of healthcare reform measures, including the impact of the U.S. excise tax on medical devices, reductions in reimbursement levels by third-party payors and cost containment efforts of healthcare purchasing organizations; dependence on new product development, technological advances and innovation; shifts in the product category or regional sales mix of our products and services; supply and prices of raw materials and products; control of costs and expenses; our ability to obtain and maintain adequate intellectual property protection; our ability to successfully integrate acquired businesses; our ability to form and implement alliances; challenges relating to changes in and compliance with governmental laws and regulations affecting our U.S. and international businesses, including regulations of the U.S. Food and Drug Administration (FDA) and foreign government regulators, such as more stringent requirements for regulatory clearance of our products; our ability to remediate matters identified in any inspectional observations or warning letters issued by the FDA; changes in tax obligations arising from tax reform measures or examinations by tax authorities; product liability and intellectual property litigation losses; our ability to retain the independent agents and distributors who market our products; our dependence on a limited number of suppliers for key raw materials and outsourced activities; changes in general industry and market conditions, including domestic and international growth rates and general domestic and international economic conditions, including interest rate and currency exchange rate fluctuations; and the impact of the ongoing economic uncertainty affecting countries in the Euro zone on our ability to collect accounts receivable in affected countries. For a further list and description of such risks and uncertainties, see our periodic reports filed with the U.S. Securities and Exchange Commission. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be set forth in our periodic reports. Readers of this document are cautioned not to place undue reliance on these forward-looking statements, since, while we believe the assumptions on which the forward-looking statements are based are reasonable, there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this document.
ZIMMER HOLDINGS, INC.
CONSOLIDATED STATEMENTS OF EARNINGS
FOR THE THREE MONTHS ENDED MARCH 31, 2014 and 2013
(in millions, except per share amounts, unaudited)
2014 2013
---- ----
Net Sales $1,161.5 $1,138.9
Cost of products sold 305.4 292.9
----- -----
Gross Profit 856.1 846.0
----- -----
Research and development 47.5 53.5
Selling, general and
administrative 464.3 460.8
Special items 45.9 33.5
---- ----
Operating expenses 557.7 547.8
----- -----
Operating Profit 298.4 298.2
Interest income 2.5 3.7
Interest expense (15.0) (18.2)
----- -----
Earnings before income
taxes 285.9 283.7
Provision for income taxes 64.8 65.7
---- ----
Net earnings 221.1 218.0
Less: Net loss
attributable to
noncontrolling interest (0.4) (0.6)
---- ----
Net Earnings of Zimmer
Holdings, Inc. $221.5 $218.6
====== ======
Earnings Per Common Share
Basic $1.31 $1.30
Diluted $1.29 $1.28
Weighted Average Common Shares Outstanding
Basic 169.1 168.7
Diluted 171.8 170.7
Cash dividends declared per
common share $0.22 $0.20
ZIMMER HOLDINGS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in millions, unaudited)
March 31, December 31,
2014 2013
---- ----
Assets
Current Assets:
Cash and cash
equivalents $882.7 $1,080.6
Short-term
investments 705.4 727.0
Receivables, net 939.1 936.6
Inventories 1,125.9 1,074.5
Other current assets 393.6 379.0
----- -----
Total current assets 4,046.7 4,197.7
Property, plant and
equipment, net 1,235.6 1,224.7
Goodwill 2,623.3 2,611.2
Intangible assets,
net 671.0 707.7
Other assets 803.5 839.3
----- -----
Total Assets $9,380.1 $9,580.6
======== ========
Liabilities and
Stockholders' Equity
Current liabilities $918.7 $1,031.6
Other long-term
liabilities 543.6 576.6
Long-term debt 1,680.1 1,672.3
Stockholders' equity 6,237.7 6,300.1
------- -------
Total Liabilities and
Stockholders' Equity $9,380.1 $9,580.6
======== ========
ZIMMER HOLDINGS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE THREE MONTHS ENDED MARCH 31, 2014 and 2013
(in millions, unaudited)
2014 2013
---- ----
Cash flows provided by (used in) operating activities
Net earnings $221.1 $218.0
Depreciation and amortization 101.0 85.1
Share-based compensation 11.2 14.0
Income tax benefits from employee stock
compensation plans 20.2 13.6
Excess income tax benefits from employee
stock compensation plans (5.4) (3.5)
Inventory step-up 2.5 0.8
Changes in operating assets and liabilities, net of acquired assets
and liabilities
Income taxes (75.6) 17.6
Receivables 5.3 (44.2)
Inventories (56.6) (59.7)
Accounts payable and accrued expenses (56.0) (31.3)
Other assets and liabilities 21.1 (29.9)
---- -----
Net cash provided by operating activities 188.8 180.5
----- -----
Cash flows provided by (used in) investing activities
Additions to instruments (49.4) (57.5)
Additions to other property, plant and
equipment (31.4) (17.9)
Purchases of investments (600.7) (94.8)
Sales of investments 583.1 232.0
Investments in other assets - (8.8)
--- ----
Net cash provided by (used in) investing
activities (98.4) 53.0
----- ----
Cash flows provided by (used in) financing activities
Net payments under revolving credit
facilities 0.2 (100.1)
Dividends paid to stockholders (34.0) (30.9)
Proceeds from employee stock compensation
plans 138.2 67.0
Excess income tax benefits from employee
stock compensation plans 5.4 3.5
Repurchase of common stock (400.5) (392.0)
------ ------
Net cash used in financing activities (290.7) (452.5)
------ ------
Effect of exchange rates on cash and cash equivalents 2.4 (8.3)
--- ----
Decrease in cash and cash equivalents (197.9) (227.3)
Cash and cash equivalents, beginning of period 1,080.6 884.3
------- -----
Cash and cash equivalents, end of period $882.7 $657.0
====== ======
ZIMMER HOLDINGS, INC.
NET SALES BY GEOGRAPHIC SEGMENT
FOR THE THREE MONTHS ENDED MARCH 31, 2014 and 2013
(in millions, unaudited)
Three Months
Ended March 31,
----------------
2014 2013 % Inc
---- ---- -----
Americas $638.7 $634.7 1%
Europe 326.9 307.5 6
Asia Pacific 195.9 196.7 -
----- -----
Total $1,161.5 $1,138.9 2
======== ========
ZIMMER HOLDINGS, INC.
NET SALES BY PRODUCT CATEGORY
FOR THE THREE MONTHS ENDED MARCH 31, 2014 and 2013
(in millions, unaudited)
Three Months
Ended March 31,
----------------
2014 2013 % Inc/(Dec)
---- ---- -----------
Reconstructive
Knees $487.9 $471.0 4%
Hips 331.7 330.8 -
Extremities 52.1 47.8 9
---- ----
871.7 849.6 3
Dental 61.0 59.7 2
Trauma 79.7 82.0 (3)
Spine 48.3 47.7 1
Surgical and other 100.8 99.9 1
----- ----
Total $1,161.5 $1,138.9 2
======== ========
ZIMMER HOLDINGS, INC.
RECONCILIATION OF REPORTED % GROWTH TO
CONSTANT CURRENCY % GROWTH
(unaudited)
For the Three Months
Ended
March 31, 2014
--------------
Foreign Constant
Reported Exchange Currency
% Change Impact % Change
-------- ------ --------
Geographic Segments
Americas 1% - % 1%
Europe 6 2 4
Asia Pacific - (8) 8
Total 2 (1) 3
Product Categories
Reconstructive
Americas 2 - 2
Europe 6 2 4
Asia Pacific - (9) 9
Total 3 (1) 4
Knees
Americas 3 - 3
Europe 7 2 5
Asia Pacific - (10) 10
Total 4 (1) 5
Hips
Americas (1) (1) -
Europe 3 2 1
Asia Pacific (2) (9) 7
Total - (2) 2
Extremities 9 - 9
Dental 2 - 2
Trauma (3) (2) (1)
Spine 1 - 1
Surgical and
other 1 (2) 3
ZIMMER HOLDINGS, INC.
Reconciliation of Net Earnings and Adjusted Net
Earnings
For the Three Months Ended March 31, 2014 and 2013
(in millions, unaudited)
Three
Months
Ended
March
31,
------
2014 2013
---- ----
Net Earnings of Zimmer
Holdings, Inc. $221.5 $218.6
Inventory step-up and other inventory
and manufacturing related
charges 7.7 2.2
Special items 45.9 33.5
Taxes on above items* (17.0) (13.5)
---- ----
Adjusted Net Earnings $258.1 $240.8
====== ======
* The tax effect is calculated based upon the
statutory rates for the jurisdictions where the
items
were incurred.
ZIMMER HOLDINGS, INC.
Reconciliation of Diluted EPS and Adjusted Diluted
EPS
For the Three Months Ended March 31, 2014 and 2013
(unaudited)
Three
Months
Ended
March
31,
------
2014 2013
---- ----
Diluted EPS $1.29 $1.28
Inventory step-up and other inventory
and manufacturing related
charges 0.04 0.01
Special items 0.27 0.20
Taxes on above items* (0.10) (0.08)
---- ----
Adjusted Diluted EPS $1.50 $1.41
===== =====
* The tax effect is calculated based upon the
statutory rates for the jurisdictions where the
items
were incurred.
ZIMMER HOLDINGS, INC.
Reconciliation of 2014 Projected Diluted EPS
and Projected Adjusted Diluted EPS
(unaudited)
Projected Year Ended December
31, 2014: Low High
--- ----
Diluted EPS $4.90 $5.10
Inventory step-up and other inventory and
manufacturing
related charges and special
items 1.48 1.48
Taxes on above items* (0.38) (0.38)
---- ----
Adjusted Diluted EPS $6.00 $6.20
===== =====
* The tax effect is calculated based upon the
statutory rates for the jurisdictions where the
items
have been or are projected to be incurred.
Logo - http://photos.prnewswire.com/prnh/20131216/MM33947LOGO
SOURCE Zimmer Holdings, Inc.
